title: Hizentra for the treatment of primary immunodeficiency.
abstract: Immunoglobulin (IgG) replacement therapy has been the cornerstone of treatment for primary immunodeficiency disease for nearly 60 years. During this time, research has continually refined the target IgG trough level and IgG replacement dosages to allow patients with primary immunodeficiency disease to achieve effective protection from infection. Manufacturers have also improved IgG formulations to allow patients to receive clinically beneficial dosages of IgG replacement with improved safety and tolerability. This review will introduce Hizentra(®), a highly concentrated (20%) IgG solution for subcutaneous (sc.) infusion, discuss its manufacturing process and pharmacokinetic profile and review its tolerability and efficacy data as evaluated in clinical trials. New highly concentrated sc. IgG products may improve patient quality of life and adherence to therapy because of the flexible dosing options, fewer infusion sites and less infusion time, compared with less concentrated sc. IgG products, resulting in favorable patient outcomes consistent with higher steady-state IgG levels.
authors.affiliation: Dallas Allergy Immunology Research, 7777 Forest Ln, Building B, Suite 332, Dallas, TX 75230, USA.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Wasserman
mesh_terms: D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*
chemical_list: C558471:Hizentra; D007074:Immunoglobulin G
keywords: Hizentra; immunoglobulin; primary immunodeficiency; subcutaneous immunoglobulin